Omega 3 Prescription Drugs Market (2026 - 2033)

Omega 3 Prescription Drugs Market Summary

The global omega 3 prescription drugs market size was valued at USD 1.7 billion in 2025 and is projected to grow from USD 1.8 billion in 2026 to USD 3.4 billion by 2033, growing at a CAGR of 9.4% from 2026 to 2033. North America dominated the market, accounting for the largest global share of 41.3% in 2025. The market is driven by rising cases of cardiovascular diseases and the increasing use of these formulations to manage hypertriglyceridemia.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Expanding aging populations and associated chronic conditions contribute to higher demand. Ongoing research into additional applications, including neurological and inflammatory disorders, creates opportunities for product utilization. These factors, supported by physician recommendations and insurance coverage, drive consistent revenue growth in the industry.

The rising cardiovascular disease burdens and increasing demand for drugs are recognized for reducing triglycerides and supporting heart health. Growing awareness, preventive measures, and healthcare investments further drive the adoption of these formulations, contributing to industry expansion. The World Heart Federation's 2023 report highlights a 60% increase in global cardiovascular disease (CVD) deaths over three decades, from 12.1 million in 1990 to 20.5 million in 2021, with 80% of deaths occurring in low- and middle-income countries (LMICs). The age-standardized global CVD death rate decreased, but disparities persist, with higher death rates in regions like Central Europe and Sub-Saharan Africa. Key contributors include high blood pressure, air pollution, and tobacco use. The report emphasizes investing 5% of GDP in healthcare and implementing key policies, such as tobacco control and access to CVD treatments, to reduce mortality and morbidity.

To learn more about this report, Download Free Sample Report

Rising awareness of the benefits of reducing triglycerides and supporting heart health has expanded the industry. Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been shown to lower triglyceride levels, a significant risk factor for CVDs. Growing educational initiatives by healthcare organizations and manufacturers have improved public understanding of their role in managing lipid profiles and supporting cardiovascular health. Regulatory body's endorsements of drugs as effective treatments for hypertriglyceridemia have further driven adoption. Awareness campaigns highlighting clinical evidence of their efficacy have increased patient and healthcare provider demand. This trend has encouraged pharmaceutical companies to develop advanced formulations, supporting market growth in these products.

Growing healthcare expenditure and the adoption of preventive healthcare are driving the market. Increasing investments in healthcare services and awareness programs are promoting early interventions for cardiovascular diseases, encouraging the use of these drugs. The expanding aging population at higher risk for cardiovascular conditions has further elevated the demand for such products targeting lipid management. Regulatory approvals for new formulations have supported industry expansion by improving access and availability. Advancements in drug formulations, focusing on enhanced efficacy and patient compliance, are attracting broader acceptance among healthcare providers and patients, contributing to the sustained growth of this market segment.

Market Dynamics

The global omega 3 prescription drugs market is driven by the increasing burden of cardiovascular disease and severe hypertriglyceridemia, along with greater emphasis on preventive healthcare and evidence-based therapies. Prescription omega 3 products continue to gain preference over dietary supplements because they provide standardized formulations, proven efficacy for approved indications, and consistent manufacturing quality. Clinical guideline updates and increasing physician awareness are supporting broader use of purified eicosapentaenoic acid therapies for eligible patients with elevated cardiovascular risk. Market participants are also expanding generic product availability, improving patient access while increasing pricing competition. Demand remains strongest in developed healthcare systems where reimbursement and cardiovascular screening programs support prescription uptake. At the same time, manufacturers are investing in lifecycle management, regulatory approvals across additional countries, and real-world clinical evidence to strengthen market position. Challenges include reimbursement limitations in some regions, competition from generic products, and patient confusion between prescription medicines and over the counter omega 3 supplements, which can affect treatment adoption and commercial growth.

Analyst Perspective

The omega 3 prescription drugs market is transitioning from reliance on branded therapies toward a more competitive environment driven by generic adoption, evolving cardiovascular treatment guidelines, and expanding patient access. Established companies continue to leverage clinical evidence, regulatory expertise, and physician engagement to maintain market position, while generic manufacturers are improving affordability and expanding availability across multiple regions. Future growth will depend on continued evidence supporting cardiovascular risk reduction, successful reimbursement negotiations, and geographic expansion into underserved markets. Companies that balance clinical differentiation with cost competitive commercialization strategies and strong distribution networks are expected to strengthen their long-term market presence.

Expanding aging populations and associated chronic conditions contribute to higher demand. Ongoing research into additional applications, including neurological and inflammatory disorders, creates opportunities for product utilization. These factors, supported by physician recommendations and insurance coverage, drive consistent revenue growth in the industry.

The rising cardiovascular disease burdens and increasing demand for drugs are recognized for reducing triglycerides and supporting heart health. Growing awareness, preventive measures, and healthcare investments  further drive the adoption of these formulations, contributing to industry expansion. The World Heart Federation's 2023 report highlights a 60% increase in global cardiovascular disease (CVD) deaths over three decades, from 12.1 million in 1990 to 20.5 million in 2021, with 80% of deaths occurring in low- and middle-income countries (LMICs). The age-standardized global CVD death rate decreased, but disparities persist, with higher death rates in regions like Central Europe and Sub-Saharan Africa. Key contributors include high blood pressure, air pollution, and tobacco use. The report emphasizes investing 5% of GDP in healthcare and implementing key policies, such as tobacco control and access to CVD treatments, to reduce mortality and morbidity.

Rising awareness of the benefits of reducing triglycerides and supporting heart health has expanded the industry. Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been shown to lower triglyceride levels, a significant risk factor for CVDs. Growing educational initiatives by healthcare organizations and manufacturers have improved public understanding of their role in managing lipid profiles and supporting cardiovascular health. Regulatory body's endorsements of drugs as effective treatments for hypertriglyceridemia have further driven adoption. Awareness campaigns highlighting clinical evidence of their efficacy have increased patient and healthcare provider demand. This trend has encouraged pharmaceutical companies to develop advanced formulations, supporting market growth in these products.

Growing healthcare expenditure and the adoption of preventive healthcare are driving the market. Increasing investments in healthcare services and awareness programs are promoting early interventions for cardiovascular diseases, encouraging the use of these drugs. The expanding aging population at higher risk for cardiovascular conditions has further elevated the demand for such products targeting lipid management. Regulatory approvals for new formulations have supported industry expansion by improving access and availability. Advancements in drug formulations, focusing on enhanced efficacy and patient compliance, are attracting broader acceptance among healthcare providers and patients, contributing to the sustained growth of this market segment.

Drug Insights

Based on drug, the Vascepa segment led the market with the largest revenue share of 41.9% in 2025 due to the availability of multiple generic alternatives, which are significantly more affordable than branded drugs like Vascepa. Generic products, such as Lovaza, offer similar therapeutic benefits but at a lower cost, making them the preferred choice for patients and healthcare providers. The increased cost-effectiveness of generics and broader industry access drive the higher demand in the others segment, overshadowing more expensive branded prescriptions in the market.

Lovaza is projected to experience moderate growth opportunities during the forecast period. This growth is driven by the rising prevalence of cardiovascular diseases, increased awareness of lipid management, and the expanding adoption of omega-3 therapies. However, growth may be tempered by competition from generic omega-3 products. In addition, market dynamics will be influenced by pricing pressures and regulatory considerations. Despite these challenges, Lovaza's established market presence and proven efficacy in managing hypertriglyceridemia position it for steady growth in the coming years.

Application Insights

Based on application, the cardiovascular segment led the market with the largest revenue share of 87.5% in 2025. This dominance is driven by the increasing prevalence of cardiovascular diseases, such as hyperlipidemia and atherosclerosis, which are major contributors to global morbidity and mortality. Omega-3 fatty acids, particularly EPA and DHA, are widely recognized for their benefits in reducing triglyceride levels, improving lipid profiles, and supporting overall heart health. As healthcare providers increasingly prescribe omega-3 medications like Lovaza for cardiovascular management, the demand within this segment continues to grow, making it the largest contributor to market revenue.

Others is expected to show moderate growth over the forecast period. This segment includes rheumatoid arthritis, diabetes management, and chronic kidney disease. For rheumatoid arthritis, they help reduce inflammation and joint pain. In diabetes management, the drug enhances insulin sensitivity and reduces inflammation. Furthermore, omega-3s play a role in managing chronic kidney disease by improving kidney function and inflammation.

Distribution Channel Insights

Based on distribution channel, the retail pharmacy segment led the market with the largest revenue share of 53.7% in 2025 due to its wide accessibility and consumer convenience. Retail pharmacies are easily accessible to patients, allowing them to purchase drugs without requiring hospital visits or specialized healthcare facilities. This accessibility and the ability to receive pharmacist advice drive higher consumer confidence and demand. Retail pharmacies also benefit from established supply chains, facilitating the availability of omega-3 drugs for a larger patient base. As the awareness of omega-3's health benefits grows, retail pharmacies remain a primary channel for distributing these drugs, contributing significantly to market dominance.

To learn more about this report, Download Free Sample Report

The online pharmacy segment is expected to witness moderate growth due to the increasing consumer preference for convenient and accessible healthcare solutions. The rise in e-commerce, along with the growing trend of telemedicine and home delivery services, has facilitated easier access to prescription medications. Moreover, the ongoing digital transformation in the healthcare sector, coupled with the ability to compare prices and offers, is driving more consumers to opt for online pharmacies. However, regulatory challenges and concerns regarding the authenticity of online drugs may temper growth prospects in this segment.

Regional Insights

North America dominated the omega 3 prescription drugs market with the largest revenue share of 41.3% in 2025 and is anticipated to grow significantly over the forecast period. As per the CDC in 2022, in the U.S., heart-related diseases are the leading cause of death for both sexes and members of the majority of racial and ethnic groups. Cardiovascular disease accounts for the death of one person in the U.S. every 36 seconds. The region's rising concern over heart-related disorders is driving up medication demand. Moreover, high triglyceride level is associated with obesity. Two out of three U.S. adults are overweight or obese, which accounts for 69 percent, and one out of three are obese, accounting for 36%. Lowering triglyceride levels with omega 3 prescription drugs further drives market growth in this region.

To learn more about this report, Download Free Sample Report

U.S. Omega 3 Prescription Drugs Market Trends

The omega 3 prescription drugs market in the U.S. held the largest share in the North America region in 2025, driven by the increasing prevalence of cardiovascular diseases and the growing demand for effective triglyceride management. The market benefits from expanding awareness about the therapeutic applications of omega-3 and its role in reducing the risks of heart disease. Advancements in drug formulations and the growing acceptance of omega-3 prescriptions within treatment protocols for cardiovascular conditions further contribute to market growth. The continuous development of new products and combinations is expected to enhance treatment options, maintaining the U.S. market's dominance.

Europe Omega 3 Prescription Drugs Market Trends

The omega 3 prescription drugs market in Europe is experiencing significant growth due to increasing awareness of cardiovascular disease prevention and the growing adoption of these drugs. The aging population in Europe, which is more susceptible to cardiovascular conditions, further drives the demand for these drugs. Rising healthcare expenditure and advancements in omega-3 formulations for chronic disease management are contributing to market growth. Regulatory support for novel omega-3 treatments and expanding prescription options in key markets such as Germany, France, and the UK are expected to enhance the overall market landscape.

The UK omega 3 prescription drugs market is expected to witness significant growth, driven by an increasing focus on heart health and raising awareness of the benefits of omega-3 in cardiovascular disease management. The NHS has integrated omega-3 prescriptions into treatment plans for patients with high triglyceride levels and heart-related conditions. Key pharmaceutical companies in the UK are developing new omega-3 formulations, contributing to market growth. Furthermore, government initiatives to improve public health and the availability of prescription omega-3 medications are supporting market expansion.

The omega 3 prescription drugs market in Germany holds a prominent share in Europe, driven by its strong healthcare system and increasing demand for effective cardiovascular treatments. The adoption of omega-3 for managing high triglyceride levels and supporting heart health is expanding, with a growing emphasis on evidence-based therapies. Regulatory support for prescription omega-3 products and advancements in formulation technologies are contributing to market growth. In addition, the country’s focus on improving patient access to prescription omega-3 therapies through healthcare infrastructure development is expected to continue supporting market expansion.

Asia Pacific Omega 3 Prescription Drugs Market Trends

The omega 3 prescription drugs market in Asia Pacific is experiencing rapid growth, attributed to rising healthcare expenditure, an aging population, and increased consumer awareness of cardiovascular health. The region’s rising incidence of chronic diseases such as cardiovascular disorders, diabetes, and hypertension is contributing to the growing demand for these prescription therapies. Key markets such as China, India, and Japan drive the demand for omega-3 drugs, with government initiatives to improve healthcare access and treatment protocols supporting market development. The expansion of pharmaceutical companies' product portfolios and distribution networks is expected to enhance market penetration.

China omega 3 prescription drugs market is witnessing moderate growth due to the increasing prevalence of cardiovascular diseases and the country’s expanding aging population. Government efforts to improve healthcare infrastructure and increase access to prescription drugs are fostering market development. Furthermore, the growing adoption of omega-3-based therapies in managing triglyceride levels and preventing heart disease is expected to continue driving demand. The presence of local and international pharmaceutical companies further supports the availability and accessibility of omega-3 prescription products.

The omega 3 prescription drugs market in Japan is characterized by high consumer awareness and a well-established healthcare system. The growing prevalence of cardiovascular conditions, coupled with the country’s aging population, is driving demand for omega-3 prescription medications. Japanese healthcare providers are increasingly recommending omega-3 as part of treatment protocols for heart disease prevention. Ongoing research and developing novel omega-3 formulations are contributing to market growth. Furthermore, collaborations between pharmaceutical companies and healthcare providers are facilitating greater access to omega-3 prescriptions across the country.

Latin America Omega 3 Prescription Drugs Market Trends

The Omega 3 prescription drugs market in Latin America is driven by increasing demand for cardiovascular health management. The market is expected to expand with more focus on preventive healthcare, particularly as the prevalence of heart diseases rises. Key trends include advancements in drug formulations for higher efficacy and the development of plant-based omega-3 alternatives to cater to vegetarian preferences. The ongoing research into high-concentration formulations and digital health integration further supports growth.

Brazil omega 3 prescription drugs market is witnessing steady growth, fueled by an increasing focus on healthcare accessibility and a rising prevalence of cardiovascular conditions. Government policies to improve healthcare coverage and expand access to prescription drugs support market expansion. The demand for omega-3 prescription drugs, particularly for managing heart health and triglyceride levels, is increasing. Moreover, growing consumer awareness of the benefits of omega-3 for heart disease prevention is expected to continue driving the market forward.

Middle East & Africa Omega 3 Prescription Drugs Market Trends

The omega 3 prescription drugs market in MEA is experiencing growth due to rising awareness about cardiovascular health and the increasing prevalence of related diseases. Key markets such as South Africa, UAE, and Saudi Arabia are witnessing an uptick in demand for omega-3 prescription products. Governments in the region are focusing on improving healthcare systems and expanding access to medications, further stimulating market growth. Collaborative efforts between healthcare providers and pharmaceutical companies are helping to improve the availability of omega-3 prescription drugs, driving market expansion in the MEA region.

Saudi Arabia omega 3 prescription drugs market is expanding, driven by increasing healthcare initiatives and a rising focus on cardiovascular disease management. The country’s Vision 2030 framework emphasizes improving health outcomes, contributing to greater demand for effective treatments like omega-3 for heart disease and high triglyceride levels. With an increasing prevalence of lifestyle-related diseases, omega-3 prescriptions are becoming an essential part of treatment regimens. The government’s efforts to improve healthcare infrastructure and drug accessibility, along with growing awareness of the health benefits of omega-3, are expected to support market growth. Key international and local pharmaceutical companies are expanding their regional offerings, enhancing availability and competition.

Key Omega 3 Prescription Drugs Company Insights

Key players in the global market include Amarin Pharmaceuticals Ireland Limited, Woodward Pharma Services LLC, Mankind Pharma, GLW Pharma GMBH, CSPC Pharmaceutical Group Limited, and Sofgen. These companies are major contributors to the market, focusing on developing Omega-3-based products aimed at improving cardiovascular health. Their strategic partnerships, continuous research, and investment in innovative formulations play a vital role in driving market growth. In addition, these companies are working to expand their global reach and enhance product accessibility, positioning themselves as key players in the evolving market.

Recent Developments

• In September 2024, Amarin Corporation presented research highlighting VASCEPA/VAZKEPA's impact on reducing cardiovascular risk in diabetic patients with prior CABG (REDUCE-IT analysis) and its anti-Lp(a) oxidation effects under hyperglycemic conditions. Key studies include ischemic event reduction in high-risk patients and eicosapentaenoic acid's role in addressing cardiovascular complications. VASCEPA, approved globally for managing persistent cardiovascular risk in statin-treated patients, remains central to advancing treatment for at-risk populations.

• In July 2024, Amarin Corporation announced the Portuguese Ministry of Health’s approval for the national reimbursement of VAZKEPA (icosapent ethyl) to reduce cardiovascular events in adults with elevated triglycerides and high cardiovascular risk. This decision marks the eighth reimbursement for VAZKEPA in Europe and enables commercialization in Portugal from August 2024. Cardiovascular disease impacts 10.7% of Portuguese adults aged 45-79, contributing to 29% of annual mortality. This reimbursement aligns with Amarin's strategy to expand European access and address significant cardiovascular health burdens.

• In July 2024, Amarin Corporation announced regulatory approval for VASCEPA (icosapent ethyl) in Mainland China by the National Medical Products Administration (NMPA). The approval allows its use as an adjunct to statin therapy to reduce cardiovascular risk in adults with elevated triglycerides (≥150 mg/dL) and high-risk factors. Amarin’s partner, EddingPharm, will pursue inclusion on China’s National Reimbursement Drug Listing (NRDL) and expand commercialization efforts. Cardiovascular disease accounts for 44-47% of deaths in China, with over 330 million patients affected. Amarin will receive a USD15 million milestone payment and royalties from sales.

• In May 2024, Amarin Corporation announced NMPA approval for VASCEPA (icosapent ethyl) in China to reduce cardiovascular risk in adults with elevated triglycerides (≥150 mg/dL) and high-risk factors as an adjunct to statin therapy. Partner EddingPharm will seek inclusion on the National Reimbursement Drug Listing (NRDL) and enhance commercialization.

Global Omega 3 Prescription Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global omega 3 prescription market report based on drugs, application, distribution channel, and regions:

To learn more about this report, Download Free Sample Report

• Drug Outlook (Revenue, USD Million, 2021 - 2033)

  • Vascepa

  • Lovaza

  • Others

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Cardiovascular

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The omega 3 prescription drugs market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing—reconciling supply-side and demand-side estimates—and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each omega 3 prescription drugs segment quantified using the revenue-capture definitions in the table below.

Estimation Model 

To learn more about this report, Download Free Sample Report

The Omega 3 Prescription Drugs Market was estimated using a bottom up methodology supported by secondary research and primary validation. The study identified key manufacturers including Amarin Pharmaceuticals Ireland Limited, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, and other branded and generic suppliers. Approved products such as Vascepa, Lovaza, and other prescription omega 3 drugs were benchmarked based on regulatory approvals, commercialization status, and geographic presence. Product level revenues were estimated using annual reports, financial filings, prescription trends, pharmaceutical databases, and industry publications. Individual product revenues were aggregated to determine the overall market size and segmented by drug, application, distribution channel, and region. Market shares were assessed using company sales performance, product portfolios, and commercial reach. The findings were validated through interviews with industry experts, healthcare professionals, distributors, and secondary data triangulation to ensure accurate, reliable, and consultant grade market estimates.

Delivered Customizations

This report has been delivered with the following In-depth customizations